Literature DB >> 16542214

Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor.

Emiko Nakataki1, Seiji Yano, Yuka Matsumori, Hisatsugu Goto, Soji Kakiuchi, Hiroaki Muguruma, Yoshimi Bando, Hisanori Uehara, Hironobu Hamada, Katsumi Kito, Akihito Yokoyama, Saburo Sone.   

Abstract

Malignant pleural mesothelioma (MPM) is closely related to exposure to asbestos, and a rapid increase in the number of MPM patients in Japan is estimated in the years 2010-2050. The purpose of the present study was to establish a clinically relevant animal model that shows human patient-like progression of MPM. Here, we demonstrate that a human MPM cell line (EHMES-10) inoculated orthotopically (thoracic cavity) into severe combined immunodeficiency (SCID) mice produces highly vascularized thoracic tumors with pleural dissemination and bloody pleural effusions by 5 weeks, suggesting a patient-like progression of this cell line after orthotopic inoculation. EHMES-10 cells overexpressed vascular endothelial growth factor (VEGF), a molecule responsible for malignant effusions, and its receptor. Treatment with cisplatin, but not gemcitabine, significantly inhibited the production of pleural effusions, but it was not effective for thoracic tumors, consistent with chemotherapy refractory characteristics of MPM in patients. Our patient-like orthotopic model using EHMES-10 cells overexpressing VEGF and its receptor may be useful for examining the molecular pathogenesis of MPM and may contribute to the development of novel treatment strategies for MPM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16542214     DOI: 10.1111/j.1349-7006.2006.00163.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  20 in total

1.  Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma.

Authors:  Tadaaki Yamada; Joseph M Amann; Koji Fukuda; Shinji Takeuchi; Naoya Fujita; Hisanori Uehara; Shotaro Iwakiri; Kazumi Itoi; Konstantin Shilo; Seiji Yano; David P Carbone
Journal:  Cancer Res       Date:  2015-08-20       Impact factor: 12.701

2.  Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network.

Authors:  Qi Li; Wei Wang; Tadaaki Yamada; Kunio Matsumoto; Katsuya Sakai; Yoshimi Bando; Hisanori Uehara; Yasuhiko Nishioka; Saburo Sone; Shotaro Iwakiri; Kazumi Itoi; Teruhiro Utsugi; Kazuo Yasumoto; Seiji Yano
Journal:  Am J Pathol       Date:  2011-07-18       Impact factor: 4.307

3.  EGCG induces human mesothelioma cell death by inducing reactive oxygen species and autophagy.

Authors:  Motohiko Satoh; Yukitoshi Takemura; Hironobu Hamada; Yoshitaka Sekido; Shunichiro Kubota
Journal:  Cancer Cell Int       Date:  2013-02-23       Impact factor: 5.722

4.  The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.

Authors:  Trung The Van; Masaki Hanibuchi; Soji Kakiuchi; Seidai Sato; Takuya Kuramoto; Hisatsugu Goto; Atsushi Mitsuhashi; Yasuhiko Nishioka; Shin-Ichi Akiyama; Saburo Sone
Journal:  Cancer Chemother Pharmacol       Date:  2010-11-16       Impact factor: 3.333

5.  Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis.

Authors:  Daniele Martarelli; Alfonso Catalano; Antonio Procopio; Sara Orecchia; Roberta Libener; Giorgio Santoni
Journal:  BMC Cancer       Date:  2006-05-17       Impact factor: 4.430

6.  Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma.

Authors:  Qi Li; Wei Wang; Yusuke Machino; Tadaaki Yamada; Kenji Kita; Masanobu Oshima; Yoshitaka Sekido; Mami Tsuchiya; Yui Suzuki; Ken-ichiro Nan-Ya; Shigeru Iida; Kazuyasu Nakamura; Shotaro Iwakiri; Kazumi Itoi; Seiji Yano
Journal:  Cancer Sci       Date:  2014-12-18       Impact factor: 6.716

7.  In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.

Authors:  Shigeki Nanjo; Takayuki Nakagawa; Shinji Takeuchi; Kenji Kita; Koji Fukuda; Mitsutoshi Nakada; Hisanori Uehara; Hiroshi Nishihara; Eiji Hara; Hidetaka Uramoto; Fumihiro Tanaka; Seiji Yano
Journal:  Cancer Sci       Date:  2015-02-17       Impact factor: 6.716

8.  Zoledronic acid produces combinatory anti-tumor effects with cisplatin on mesothelioma by increasing p53 expression levels.

Authors:  Shinya Okamoto; Yuanyuan Jiang; Kiyoko Kawamura; Masato Shingyoji; Toshihiko Fukamachi; Yuji Tada; Yuichi Takiguchi; Koichiro Tatsumi; Hideaki Shimada; Kenzo Hiroshima; Hiroshi Kobayashi; Masatoshi Tagawa
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

9.  Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma.

Authors:  Jun Kurai; Hiroki Chikumi; Kiyoshi Hashimoto; Miyako Takata; Takanori Sako; Kosuke Yamaguchi; Naoki Kinoshita; Masanari Watanabe; Hirokazu Touge; Haruhiko Makino; Tadashi Igishi; Hironobu Hamada; Seiji Yano; Eiji Shimizu
Journal:  Int J Oncol       Date:  2012-08-24       Impact factor: 5.650

10.  Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo.

Authors:  Seigo Miyoshi; Hironobu Hamada; Naohiko Hamaguchi; Aki Kato; Hitoshi Katayama; Kazunori Irifune; Ryoji Ito; Tatsuhiko Miyazaki; Takafumi Okura; Jitsuo Higaki
Journal:  Int J Oncol       Date:  2012-05-08       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.